Treating diabetes using oral agents

Primary Care - Clinics in Office Practice

Volumn 30, Issue 3, 2003, Pages 527-541

  Malik, Tariq ^a   Trence, Dace L ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MICRONASE XL; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

DRUG EFFECT; DRUG EFFICACY; FLATULENCE; GASTROINTESTINAL SYMPTOM; HIGH RISK POPULATION; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SYNTHESIS; LACTIC ACIDOSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT FAILURE; WEIGHT GAIN;

EID: 0141541631     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(03)00039-3     Document Type: Review

References (34)

1. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002;287:360-72.
2. Skaer TL, Sclar DA, Markowski DJ, et al. Effect of value-added utilities on prescription refill compliance and Medicaid health expenditures - a study of patients with non-insulin-dependent diabetes mellitus. J Clin Pharm Ther 1993;18:295-9.
3. Boccuzzi SJ, Wogen J, Fox J, et al. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care 2001;24:1411-5.
4. Stephens JM, Blak BT, Gold KF, et al. Persistance patterns with oral hypoglycemic agents in type 2 diabetes. Journal Clinical Outcomes Management 2002;9:491-9.
5. Branch W, Malik T. Using "windows of opportunity" in brief interviews to understand patients' concerns. JAMA 1993;269:13:166-7.
6. American Diabetes Association. Translation of the diabetes nutrition recommendations for health care institutions. Diabetes Care 1997;20:106-8.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
8. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997;26:511-21.
9. Simonson DC, Ferrannini E, Bevilacqua S, et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 1984;33:838-45.
10. Schade DS, Jovanovic L, Schneider J. A placebo controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998;38:636-41.
11. Wright A, Burden ACF, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57) Group. Diabetes Care 2002;25:330-6.
12. Goldberg R, Einhorn D, Lucas C, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21:1462-9.
13. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycemia in the treatment of type 2 diabetes? Int J Obes Relat Metab Disord 2000;24(Suppl 3):S21-31.
14. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660-5.
15. Keilson L, Mather S, Walther YH, et al. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:1081-6.
16. Hundal R, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes mellitus. Diabetes 2000;49:2063-9.
17. Cusi K, DeFronzo R. Metformin: a review of its metabolic effects. Diabetes Reviews 1998;6:89-130.
18. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
19. Knowler WC, Barrett-Connor E, Fowler SE, et al. The Diabetes Prevention Program Research group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002;346:393-403.
20. Johansen K. Efficiency of Metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999;22:33-7.
21. Misbin R, Green L, Stadel B, et al. Lactic acidosis in patients with diabetes treated with metformin. N Eng J Med 1998;338:265-6.
22. Lebowitz H. α-glucosidase inhibitors as agents in the treatment of diabetes mellitus. Diabetes Reviews 1998;6:132-45.
23. Ahmann AJ, Riddle MC. Oral pharmacological agents. In: Leahy J, Clark N, Cefalu, editors. Medical management of diabetes mellitus. New York: Marcel Dekker, Inc.; 2000. p. 275-6.
24. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000;106:467-72.
25. Maggs D, Buchanan T, Burant C, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:176-85.
26. Parulkar AA, Pendergast ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
27. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998;338:861-6.
28. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
29. Delea T, Hagiwara M, Edelsberg J, et al. Exposure to glitazone antidiabetics and risk of heart failure among persons with type 2 diabetes: a retrospective population-based cohort analysis. J Am Coll Cardiol 2002;39(Suppl A):858-63.
30. Bloomgarden Z, Futterweit W, Poretsky L. Use of insulin-sensitizing agents in patients with polycystic ovary syndrome. Endocr Pract 2001;7:279-86.
31. Cavaghan MK, Ehrmann DA, Byrne MM, et al. Treatment with the oral agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997;100:530-7.
32. Futterweit W. Polycystic ovarian syndrome: clinical perspectives and management. Obstet Gynecol Surv 1999;54:403-13.
33. Palmer J. Predicting IDDM: use of humoral immune markers. Diabetes Reviews 1993;1:104-15.
34. Lindeman R, Romero L, Hundley R, et al. Prevalence of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly population. Diabetes Care 1998;21:959-66.